BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miller DS, Blessing JA, Ramondetta LM, Pham HQ, Tewari KS, Landrum LM, Brown J, Mannel RS. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol 2014;32:2744-9. [PMID: 25071133 DOI: 10.1200/JCO.2013.54.7448] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Kunos CA, Chu E, Makower D, Kaubisch A, Sznol M, Ivy SP. Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers. Front Oncol 2017;7:62. [PMID: 28421163 DOI: 10.3389/fonc.2017.00062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
2 Annunziata CM, Kohn EC. Clinical trials in gynecologic oncology: Past, present, and future. Gynecol Oncol 2018;148:393-402. [PMID: 29212614 DOI: 10.1016/j.ygyno.2017.11.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Ivanova A, Paul B, Marchenko O, Song G, Patel N, Moschos SJ. Nine-year change in statistical design, profile, and success rates of Phase II oncology trials. J Biopharm Stat 2016;26:141-9. [PMID: 26368744 DOI: 10.1080/10543406.2015.1092030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]